THE 1ST INTERNATIONAL UROKINASE WARFARIN TRIAL IN COLORECTAL-CANCER
THE 1ST INTERNATIONAL UROKINASE WARFARIN TRIAL IN COLORECTAL-CANCER
复制标题
DOI：
10.1007/bf01831705
复制
发表时间：
1991-01-01
影响因子：
4
通讯作者：
DALY, L
中科院分区：
文献类型：
--
作者：
DALY, L
344例Dukes分期为B或C的可手术结直肠腺癌患者进入一项随机对照试验，研究术中和术后静脉注射尿激酶和/或长期华法林钠治疗。试验的析因设计允许单独评价每种治疗。两组患者的年龄、性别、Dukes分期、肿瘤部位无明显差异。使用寿命表方法，估计术后6年的生存率和无复发/转移生存率。两种治疗对这些终点均无显著影响。
Three hundred and forty-four patients with operable colorectal adenocarcinoma, Dukes' stage B or C, were entered into a randomized controlled trial of intraoperative and postoperative intravenous urokinase and/or long-term sodium warfarin therapy. The factorial design of the trial allowed evaluation of each therapy separately. Age, sex, Dukes' stage and cancer site were similar in the treatment groups. Using life-table methods, survival and recurrence/metastases free survival were estimated up to 6 years postoperatively. No significant effects of either therapy on these endpoints were found.